Nuvalent, Inc. (NUVL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$123.960.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put NUVL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisRelatively steady — typically moves about 1% a day.
View RiskNot enough reads yet
NUVL's growth relies on sector trends improving, particularly if bellwethers like VRTX and REGN continue to perform well. Revenue performance has been steady, but the company remains unprofitable over the past year. NUVL trades at a multiple that lacks a clear earnings yield, reflecting its unprofitability. The market backdrop is currently risk-off, with a 27% probability of missing expectations in the next quarter. If sector leaders begin to miss or guide lower, the supportive trends for NUVL could fade. Peer multiples imply a price about 27% below where it trades. This read is provisional.
Trailing returns as of 2026-07-16. NUVL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering NUVL (as of Jul 2026).
Based on 12 Wall Street analysts offering 12-month price targets for NUVL in the last 4 months.
Continue this research
Compare NUVL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NUVL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put NUVL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Entry into Merger Agreement with GSK
Acquisition confirms growth strategy with GSK.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $123.96
The last 12 months of price, then the range of analyst 12-month targets from today’s $123.96.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Entry into Merger Agreement with GSK
Acquisition aligns with growth in oncology.
Advances: Entry into Merger Agreement with GSK
GSK's investment boosts oncology strategy.